36
Molecular Techniques
25. Kline MJ, W ilkinson EJ, Askeland R,
et al. DNA tetraploidy in Feulgen-
stained bladder washings assessed by
image cytometry.
A n a l Q u a n t C yto l H is to l
1995;17:129-134.
26. Chrouser K, Leibovich B, Bergstralh E,
et al. Bladder cancer risk following
primary and adjuvant external beam
radiation for prostate cancer.
J U ro l
2005;174:107-110. discussion 110-111.
27. Bartoletti R, Cai T, Dal Canto M, et al.
M ultiplex polymerase chain reaction for
microsatellite analysis o f urine sediment
cells: a rapid and inexpensive method for
diagnosing and m onitoring superficial
transitional bladder cell carcinoma.
J U ro l
2006;175:2032-2037. discussion 2037.
28. Frigerio S, Padberg BC, Strebel RT, et al.
Improved detection o f bladder carci-
noma cells in voided urine by standard-
ized microsatellite analysis.
In t J C ancer
2007;121:329-338.
29. Dulaimi E, Uzzo RG, Greenberg RE, et al.
Detection o f bladder cancer in urine by a
tum or suppressor gene hypermethylation
panel.
C lin Cancer Res
2004;10:1887-1893.
30. Hoque MO, Begum S, Topaloglu O, et al.
Quantitation o f promoter m ethylation of
m ultiple genes in urine DNA and blad-
der cancer detection.
J N a tl C ancer In s t
2006;98:996-1004.
31. Shin HJ, Shin DM, Tarco E, et al. Detec-
tion o f numerical aberrations o f chromo-
somes 7 and 9 in cytologic specimens of
pleural malignant mesothelioma.
C ancer
2003;99:233-239.
32. Illei PB, Rusch VW, Zakowski MF, et al.
Homozygous deletion of CDKN2A and
codeletion o f the methylthioadenosine
phosphorylase gene in the m ajority of
pleural mesotheliomas.
C lin C ancer Res
2003;9:2108-2113.
33. Wong L, Zhou J, Anderson D, et al.
Inactivation o f p16INK4a expression in
malignant mesothelioma by methylation.
L u n g C ancer
2002;38:131-136.
34. Sokolova IA, Bubendorf L, O'Hare A, et
al. A fluorescence in situ hybridization-
based assay for improved detection of
lung cancer cells in bronchial washing
specimens.
C ancer
2002;96:306-315.
35. Romeo MS, Sokolova IA, M orrison LE,
et al. Chromosomal abnormalities in
non-small cell lung carcinomas and in
bronchial epithelia o f high-risk smok-
ers detected by multi-target interphase
fluorescence in situ hybridization.
J M o l
D ia g n
2003;5:103-112.
36. Bubendorf L, M uller P, Joos L, et al.
Multitarget FISH analysis in the diag-
nosis o f lung cancer.
A m J C lin P a th o l
2005;123:516-523.
37. Halling KC, Rickman OB, Kipp BR, et al.
A comparison of cytology and fluores-
cence in situ hybridization for the detec-
tion o f lung cancer in bronchoscopic
specimens.
C hest
2006;130:694-701.
38. Jiang F, Caraway NP, Nebiyou Bekele B,
et al. Surfactant protein A gene deletion
and prognostics for patients w ith stage I
non-small cell lung cancer.
C lin C ancer
Res
2005;11:5417-5424.
39. Li R Todd NW, Qiu Q, et al. Genetic dele-
tions in sputum as diagnostic markers for
early detection of stage I non-small cell lung
cancer.
C lin Cancer Res
2007;13:482-487.
40. Schmiemann V, Bocking A, Kazimirek
M, et al. Methylation assay for the
diagnosis o f lung cancer on bronchial
aspirates: a cohort study.
C lin C ancer Res
2005;11:7728-7734.
41. Belinsky SA, Liechty KC, Gentry FD, et al.
Promoter hypermethylation o f multiple
genes in sputum precedes lung cancer
incidence in a high-risk cohort.
C ancer
Res
2006;66:3338-3344.
42. Shivapurkar N, Stastny V, Suzuki M, et al.
Application o f a methylation gene panel
by quantitative PCR for lung cancers.
C ancer L e tt
2007;247:56-71.
43. Jaeckle KA, Ballman KV, Rao RD, et al.
Current strategies in treatment o f oligo-
dendroglioma: evolution o f molecular
signatures of response.
J C lin O ncol
2006;24:1246-1252.
44. Scheie D, Andresen PA, Cvancarova M,
et al. Fluorescence in situ hybridization
(FISH) on touch preparations: a reliable
method for detecting loss of heterozygosity
at 1p and 19q in oligodendroglial tumors.
A m J Surg P a th o l
2006;30:828-837.
45. Brankley SM, Wang KK, Harwood AR,
et al. The development o f a fluorescence
in situ hybridization assay for the detec-
tion o f dysplasia and adenocarcinoma
in Barrett's esophagus.
J M o l D ia g n
2006;8:260-267.
46. DeHaan RD, Kipp BR, Smyrk TC, et al.
An assessment o f chromosomal altera-
tions detected by fluorescence in situ
hybridization and p16 expression in
sporadic and primary sclerosing cholangi-
tis-associated cholangiocarcinomas.
H u m
P a th o l
2007;38:491-499.
47. Klump B, Hsieh CJ, Dette S, et al.
Promoter methylation o f INK4a/ARF as
detected in bile-significance for the dif-
ferential diagnosis in biliary disease.
C lin
C ancer Res
2003;9:1773-1778.
48. Yang B, House MG, Guo M, et al. Pro-
moter methylation profiles o f tum or
suppressor genes in intrahepatic and
extrahepatic cholangiocarcinoma.
M o d
P a th o l
2005;18:412-420.
49. Khalid A, Pal R, Sasatomi E, et al. Use o f
microsatellite marker loss o f heterozygos-
ity in accurate diagnosis of pancreatico-
biliary malignancy from brush cytology
samples.
G u t
2004;53:1860-1865.
50. Willmore-Payne C, Volmar KE, Huening
MA, et al. Molecular diagnostic testing as
an adjunct to morphologic evaluation of
pancreatic ductal system brushings: poten-
tial augmentation for diagnostic sensitiv-
ity.
D ia g n C ytopathol
2007;35:218-224.
51. Tomlins SA, Rhodes DR, Perner S, et al.
Recurrent fusion o f TMPRSS2 and ETS
transcription factor genes in prostate
cancer.
Science
2005;310:644-648.
52. W olff AC, Hammond ME, Schwartz JN, et
al. American Society o f Clinical Oncology/
College o f American Pathologists guideline
recommendations for human epidermal
growth factor receptor 2 testing in breast
cancer.
J C lin O ncol
2007;25:118-145.
53. Press MF, Sauter G, Bernstein L, et al.
Diagnostic evaluation o f HER-2 as
a molecular target: an assessment of
accuracy and reproducibility o f labora-
tory testing in large, prospective, rand-
omized clinical trials.
C lin C ancer Res
2005;11:6598-6607.
54. Tapia C, Savic S, Wagner U, et al. HER2
gene status in primary breast cancers and
matched distant metastases.
B reast C ancer
Res
2007;9:R31.
55. Vocaturo A, Novelli F, Benevolo M,
et al. Chromogenic in situ hybridization
to detect HER-2/neu gene amplification
in histological and ThinPrep-processed
breast cancer fine-needle aspirates: a sen-
sitive and practical method in the trastu-
zumab era.
O ncolog ist
2006;11:878-886.
56. Tanner M, Isola J, W iklund T, et al. Topo-
isomerase IIalpha gene amplification
predicts favorable treatment response
to tailored and dose-escalated anthra-
cycline-based adjuvant chemotherapy
in HER-2/neu-amplified breast cancer:
Scandinavian Breast Group Trial 9401.
J C lin O ncol
2006;24:2428-2436.
57. Holst F, Stahl PR, Ruiz C, et al. Estrogen
receptor alpha (ESR1) gene amplification
is frequent in breast cancer.
N a t G enet
2007;39:655-660.
58. Sequist LV, Bell DW, Lynch TJ, et al.
Molecular predictors o f response to epi-
dermal growth factor receptor antagonists
in non-small-cell lung cancer.
J C lin O ncol
2007;25:587-595.
59. Riely GJ, Politi KA, M iller VA, et al.
Update on epidermal growth factor recep-
tor mutations in non-small cell lung can-
cer.
C lin C ancer Res
2006;12:7232-7241.
60. Engelman JA, Zejnullahu K, M itsudom i T,
et al. MET amplification leads to gefitinib
resistance in lung cancer by activating
ERBB3 signaling.
Science
2007;316:
1039-1043.
61. Cappuzzo F, Hirsch FR, Rossi E, et al.
Epidermal growth factor receptor gene
and protein and gefitinib sensitivity in
non-small-cell lung cancer.
J N a tl C ancer
In s t
2005;97:643-655.
62. de Villiers EM, Fauquet C, Broker TR,
et al. Classification o f papillomaviruses.
V iro lo g y
2004;324:17-27.
63. Jacobs MV, Snijders PJ, van den Brule AJ,
et al. A general primer GP5+/GP6(+)-
mediated PCR-enzyme immunoassay
method for rapid detection o f 14 high-
risk and 6 low-risk human papilloma-
virus genotypes in cervical scrapings.
J C lin M ic ro b io l
1997;35:791-795.
64. Gravitt PE, Peyton CL, Alessi TQ,
et al. Improved amplification o f genital
human papillomaviruses.
J C lin M ic ro b io l
2000;38:357-361.
65. Kleter B, van Doorn LJ, ter Schegget J,
et al. Novel short-fragment PCR assay for
highly sensitive broad-spectrum detection
o f anogenital human papillomaviruses.
A m J P a th o l
1998;153:1731-1739.
66. Puranen M, Saarikoski S, Syrjanen K,
et al. Polymerase chain reaction ampli-
fication of human papillomavirus DNA
from archival, Papanicolaou-stained cer-
vical smears.
A cta C yto l
1996;40:391-395.
67. Monsonego J, Bohbot JM, Pollini G, et
al. Performance o f the Roche AMPLICOR
human papillomavirus (HPV) test in pre-
diction o f cervical intraepithelial neopla-
sia (CIN) in women w ith abnormal PAP
smear.
G ynecol O ncol
2005;99:160-168.
68. Stevens
Mp,
Garland SM, Tabrizi SN.
Human papillomavirus genotyping using
a modified linear array detection proto-
col.
J V iro l M ethod s
2006;135:124-126.
1089
previous page 1072 ComprehensiveCytopathology 1104p 2008 read online next page 1074 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off